Showing 201 - 220 results of 102,420 for search '(( 2 fold decrease ) OR ( 5 ((((nm decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.52s Refine Results
  1. 201
  2. 202
  3. 203

    Binding sensogram (a) showing decrease in frequency of crystal immobilised with 1.5 M short aptamer exposed to different concentrations of heparanase. by Suzanne C. Simmons (319222)

    Published 2013
    “…<p>Higher concentrations of heparanase exhibited a greater decrease in frequency. Binding and regeneration sensogram (b) for addition of 800 nM heparanase to a quartz crystal immobilised with 1.5 M short aptamer. …”
  4. 204
  5. 205
  6. 206

    Bioavailable Soil Phosphorus Decreases with Increasing Elevation in a Subarctic Tundra Landscape by Andrea G. Vincent (543626)

    Published 2014
    “…Meadow soils did not have lower concentrations of Resin-P than heath soils, but they did have 2fold and 1.5fold higher concentrations of NaOH-extractable organic P and Residual P, respectively. …”
  7. 207

    DTG mice have significantly decreased troponin I phosphorylation and Serca2 expression. by Sarah N. Cilvik (495882)

    Published 2013
    “…<p>(A) Representative Western blots depicting no changes in the expression of phosphorylated protein kinase A (P-PKA) and decreased expression of phosphorylated troponin I (P-TnI) and Serca2. ß-tubulin was used as a loading control. …”
  8. 208

    Metabolites which were (A) reversibly decreased and (B) reversibly increased with smoking. by Charmion I. Cruickshank-Quinn (595143)

    Published 2014
    “…TG = triglyceride, CDP = cytidine-diphosphate, DG = diglyceride, PC = phosphatidylcholine, PS = phosphatidylserine, TG = triglyceride, PA = phosphatidic acid. Fold change ≥1.5; <i>p</i>-value≤0.05, x-axis = Log2 normalized abundance scale; Error bars represent 95% confidence; Significance values *≤0.05, **≤0.01, ***≤0.001.…”
  9. 209

    Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity by Elizabeth S. Childress (2116453)

    Published 2017
    “…Sphingosine 1-phosphate (S1P) is a pleiotropic signaling molecule that interacts with its five G-protein coupled receptors (S1P<sub>1–5</sub>) to regulate cell growth and survival and has been implicated in a variety of diseases including cancer and sickle cell disease. …”
  10. 210
  11. 211
  12. 212
  13. 213

    Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors by Maris A. Cinelli (1309419)

    Published 2017
    “…We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”
  14. 214

    WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression. by Ayana E. Morales (17756335)

    Published 2024
    “…Corresponding densitometry analysis is noted as protein fold expression compared to GAPDH for WT1, p<0.001(***), vFLIP(ns), LANA p<0.05(*), pAKT p<0.05(*), and BCL2 p <0.05(*) using two-sided, unpaired student t-tests. …”
  15. 215
  16. 216
  17. 217

    (R)-albuterol decreases cytokine mRNA levels in activated T cells by Marcela A Ferrada (41716)

    Published 2011
    “…RNA was isolated. Levels of IL-2, IL-13 and IL-6 (A, B, C) were measured by real time PCR. …”
  18. 218
  19. 219
  20. 220

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”